Opportunities of combined targeted therapy with vemurafenib and cobi-metinib in metastatic BRAF-positive cutaneous melanoma: long-term results of clinical trials
- Авторлар: Orlova K.V1, Demidov L.V1
-
Мекемелер:
- FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
- Шығарылым: № 17 (2017)
- Беттер: 55-61
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/290003
- ID: 290003
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
This article discusses in detail the possibilities of combined therapy with vemurafenib+cobimetinib (V+C) in patients with metastatic skin melanoma. In the coBRIM study, about 50% of patients in the group of combination therapy V+C had an unfavorable prognosis factor - an elevated lactate dehydrogenase (LDH) level. Despite this, the median progression-free survival and median overall survival rates were high, which points out the possibility of the use of combined targeted V+C therapy in patients with elevated LDH levels. The article also discusses the results of the BRIM7 study, which are of great interest due to the presence of a group of patients previously treated with BRAF inhibitors.
Негізгі сөздер
Толық мәтін
Авторлар туралы
K. Orlova
FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
Email: krisman03@gmail.com
PhD, Senior Clinical Researcher at the Department of Biotherapy
L. Demidov
FSBI NMRC of Oncology n.a. N.N. Blokhin of RMH
Әдебиет тізімі
- Chapman P., Hauschild A., Robert C., Haanen J., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S., Sosman J., Kirkwood J., Eggermont A., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R., Flaherty K., McArthur G. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N. Engl. J. Med. 2011;364:2507-16.
- Gogas H., Kirkwood J., Sondak V. Chemotherapy for Metastatic Melanoma. Time for a Change? Cancer. 2007;109:455-64.
- Lovly C.M., Dahlman K.B., Fohn L.E., Su Z., Dias-Santagata D., Hicks D.J., Hucks D., Berry E., Terry C., Duke M., Su Y., Sobolik-Delmaire T., Richmond A., Kelley M.C., Vnencak-Jones C.L., lafrate A.J., Sosman J., Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PloSONE. 2012;7(4):e35309.
- Ribas A., Gonzalez R., Pavlick A., Hamid O., Gajewski T., Daud A., Flaherty L, Logan T., Chmielowski B., Lewis K., Kee D., Boasberg P., Yin M., Chan I., Musib L., Choong N., Puzanov I., McArthur G. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15:954-65.
- Daud A., Pavlick A., Ribas A., Gonzalez R., Lewis K., Hamid O., Gajewski T., Puzanov I., Hsu J., Koralek D., Choong N., McArthur G. Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma. J. Clin. Oncol. 2016;34(suppl; abstr 9510).
- McArthur G., Dreno B., Atkinson V., Larkin J., Ascierto P., Daud A., Pavlick A., Gonzalez R., Lewis K., Hamid O., Gajewski T., Puzanov I., Hsu J., Park E., Ribas A. Efficacy of Long-Term Cobimetinib+Vemurafenib in Advanced BRAFV600-Mutated Melanoma: 3-Year Follow-up of coBRIM (Phase 3) and 4-year Follow-Up of BRIM7 (Phase 1b). Presented at the Society for Melanoma Research 2016 Congress, 2016 Nov 6-9, Boston (MA).
- Daud A., Pavlick A., Ribas A., Gonzalez R., Lewis K., Hamid O., Gajewski T., Puzanov I., Hsu J., Rooney I., Park E., McArthur G. Extended 5-year Follow-Up Results of a Phase 1b study (BRIM7) of Cobimetinib combined with Vemurafenib in Advanced BRAFV600-Mutated Melanoma. Presented at the Society for Melanoma Research 2017 Congress, 2017 Oct 18-21, Brisbane (Australia).
Қосымша файлдар
